Level Four Advisory Services’s Catalyst Pharmaceutical CPRX Stock Holding History

Level Four Advisory Services’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-10,510	Closed	-$141K	–	769
2023 Q2	$141K	Sell	10,510 -150	-1%	-$2.16K	0.01%	764
2023 Q1	$177K	Buy	+10,660	New	+$176K	0.01%	710

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Level Four Advisory Services's CPRX Position: Q3 2023 in Review

Level Four Advisory Services sold out of Catalyst Pharmaceutical (CPRX) in Q3 2023, closing a stake of 10,510 shares — an estimated $141K sold.

Level Four Advisory Services first reported a position in CPRX in Q1 2023 and held it in 2 quarters. The position peaked at $177K in Q1 2023. 255 funds tracked by Wall St. Rank hold CPRX as of Q3 2023.

Level Four Advisory Services reported no remaining Catalyst Pharmaceutical position as of Q3 2023 after selling out during the quarter.
Level Four Advisory Services sold 10,510 Catalyst Pharmaceutical shares in Q3 2023, an estimated $141K.
Level Four Advisory Services first reported a position in Catalyst Pharmaceutical in Q1 2023 and held it in 2 quarters.
Level Four Advisory Services's Catalyst Pharmaceutical position peaked at $177K in Q1 2023.
255 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2023.

Based on Level Four Advisory Services's 13F filing for Q3 2023, filed 13 Nov 2023.